Eleonora Cristarella, Clinical Research Nurse at National Cancer Institute of Milan, shared a post on LinkedIn about a recent article she and her colleagues co-authored, adding:
“I’m truly honored to share our new publication in the European Journal of Cancer:
‘Patient-reported outcomes with paclitaxel and ramucirumab switch maintenance in advanced gastroesophageal cancer: A secondary endpoint of the ARMANI phase 3 trial.’
The findings show that switch maintenance with paclitaxel and ramucirumab significantly delays quality of life deterioration and significantly improves key disease-related symptoms, in addition to improving survivial as already demonstrated, reinforcing the importance of patient-reported outcomes in clinical research.
I’m deeply grateful to Prof. Massimo Di Maio for his invaluable guidance during the analysis, and to Filippo Pietrantonio, Margherita Ambrosini , and Giovanni Randon for their constant support and mentorship. I’m the luckiest to work alongside such a dedicated and inspiring team.
A sincere thank you also to all the centers involved in the ARMANI study for their collaboration and commitment to advancing patient-centered research.
As a clinical research nurse, taking part in this study has been an invaluable experience that deepened my understanding of how clinical outcomes and patients’ lived experiences intersect.
Quality of life is not just a secondary endpoint, it is at the core of what we do for our patients!”
Title: Patient-reported outcomes with paclitaxel and ramucirumab switch maintenance in advanced gastroesophageal cancer: A secondary endpoint of the ARMANI phase 3 trial
Authors: Eleonora Cristarella, Margherita Ambrosini, Massimo Di Maio, Sara Lonardi, Ferdinando De Vita, Samantha Di Donato, Elisa Giommoni, Andrea Spallanzani, Alessandro Bittoni, Claudio Chini, Antonia Strippoli, Tiziana Pia Latiano, Oronzo Brunetti, Stefano Tamberi, Giovanni Gerardo Cardellino, Daniele Spada, Lorenzo Fornaro, Sara Alessandrini, Filippo Pietrantonio, Giovanni Randon
Read the Full Article on European Journal of Cancer
You can also read: DESTINY-Gastric04 Results at ASCO 2025: Trastuzumab Deruxtecan vs Ramucirumab + Paclitaxel in HER2-postitive Unresectable or Metastatic Gastric and GEJ Cancer
